Company intelligence / Profile preview
Cascade Prodrug, Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Lead candidate CPD100Li has demonstrated strong preclinical activity in hypoxic solid tumor models. The compound selectively activates under low oxygen conditions typical of solid tumors and converts to cytotoxic vinblastine only within the tumor microenvironment. Preclinical data show a significant increase in susceptibility of tumor cells to CPD100Li under hypoxic conditions. The company received FDA Orphan Drug Designation for CPD100Li for pancreatic cancer but has not yet entered clinical trials.[6][7]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (specifically hypoxia-activated prodrugs; N-oxide prodrug of vinblastine)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cascade Prodrug, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cascade Prodrug, Inc..